secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001477932-25-005919
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal
--------------------------------------------------------------------------------

- Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.
- Net loss decreased 11% in Q2 and 24% in H1 vs prior year; operating cash burn down 30% to $10.6M in H1.
- Cash & equivalents $2.3M at June 30, 2025; received $1.2M from direct offering post-quarter (director participation).
- Management expects first human diagnostics out-licensing deal in Q3 2025; confidential discussions with >10 companies.
- Conference call scheduled for August 15, 2025 at 8:30 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793225005919/0001477932-25-005919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793225005919/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-005919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer